ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Open accessThe DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.
Abstract
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2e3 years, although the range is wide, and survival may be longer for patients treated in specialized institutions. Implementation of current knowledge is highly variable among countries and within each country. The use of treatment guidelines has been associated with a significant improvement in survival. This has been achieved mainly in early breast cancer. For ABC, and particularly metastatic breast cancer (MBC), less level 1 evidence exists and only recently have international consensus guidelines been developed (ABC1 e). The ABC Consensus Conference was created by the European School of Oncology (ESO) with the ambitious goal of improving outcomes for all patients with advanced breast cancer. Backed by strong political advocacy, ABC guidelines are seeking to improve standards of care, to raise awareness about how to best meet to the needs of this underserved group of patients, and to identify research priorities so that clinical research is focused on the most important areas of unmet need. Following the work of the ESO-ABC Task Force, created in 2005, and the successful undertaking of the 1st International Consensus Guidelines Conference on ABC (ABC1), held in November 2011, the 2nd International Consensus Conference for Advanced Breast Cancer (ABC2) took place in Lisbon, Portugal, on
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“For HER-2-positive LABC, anthracyclines should not be administered concurrently with trastuzumab since this approach does not increase the pCR rate, and it could increase the risk of cardiac toxicity, based largely on studies in the metastatic setting [35,36].”
BackgroundSelf-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834 · cited 2×
“lapatinib plus capecitabine in the subset of 118 patients who were randomized in the first-line setting, having relapsed on or within 6 months of adjuvant trastuzumab, appeared similar to the effect seen in the overall trial [100].”
BackgroundResultSelf-citationEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The mTOR inhibitor everolimus when added to exemestane, in patients progressing on non-steroidal aromatase inhibitor, provided a significant PFS prolongation of about 5 months [89,90].”
BackgroundSelf-citationPertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532 · cited 1×
“The CLEOPATRA trial [96,97]; showed superior results, in terms of PFS (18.”
ResultEarly palliative care for patients with advanced cancer: a cluster-randomised controlled trial
Zimmermann, C., Swami, N., Krzyzanowska, M., Hannon, B., Leighl, N., Oza, A., Moore, M., Rydall, A., Rodin, G., Tannock, I., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62416-2 · Cited by 1,781 · cited 1×
“The multidisciplinary approach of ABC should encompass early in the history of the disease not only physical, but also functional, social, psychological, and spiritual, domains [25–27].”
BackgroundMiller, K. D., Chap, L. I., Holmes, F. A., Cobleigh, M. A., Marcom, P. K., Fehrenbacher, L., Dickler, M., Overmoyer, B. A., Reimann, J. D., Sing, A. P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.098 · Cited by 1,306 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
ResultSelf-citationGrading Strength of Recommendations and Quality of Evidence in Clinical Guidelines
Guyatt, G., Gutterman, D., Baumann, M. H., Addrizzo-Harris, D., Hylek, E. M., Phillips, B., Raskob, G., Lewis, S. Z., & Schünemann, H. (2006) · Chest · doi:10.1378/chest.129.1.174 · Cited by 1,220 · cited 1×
“Table 1 describes the grading system used [15].”
MethodCortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094 · cited 1×
“Eribulin has provided an OS benefit in heavily pretreated patients (up to 5 lines of treatment) [115] and similar PFS and OS results to capecitabine after prior treatment with an anthracycline and taxane [116].”
ResultSelf-citationRobert, N. J., Diéras, V., Glaspy, J., Brufsky, A. M., Bondarenko, I., Lipatov, O. N., Perez, E. A., Yardley, D. A., Chan, S. Y. T., Zhou, X., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.0982 · Cited by 1,064 · cited 1×
“Capecitabine has shown consistent results as first- and second-line therapy [104–112].”
Resultvon Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Research works printed but not linked: 2
- Handesman D Androgen Actions and Pharmacologic Uses, Endocrinology 2001 Philadelphia WB Saunders 2232 2242
- Wildiers H Kim SB Gonzalez-Martin A T-DM1 for HER2-positive metastatic breast cancer (MBC): primary results from TH3RESA, a phase 3 study of T-DM1 vs treatment of physician's choice 2013 Presented at the European Cancer Congress September 27–October 1 Amsterdam, The Netherlands (abstr LBA15)
Cited by
Items 201–300 of 540
Molecular imaging using PET and SPECT for identification of breast cancer subtypes
Liu, H., Chen, Y., Wu, S., Song, F., Zhang, H., & Tian, M. (2016) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000576 · Cited by 26
Tamura, K., Inoue, K., Masuda, N., Takao, S., Kashiwaba, M., Tokuda, Y., Iwata, H., Yamamoto, N., Aogi, K., Saeki, T., et al. (2017) · Cancer Science · doi:10.1111/cas.13221 · Cited by 25
Abbas, H., Erridge, S., Sodergren, M. H., Papoulas, M., Nawaz, A., Menon, K. V., Heaton, N. D., Prachalias, A. A., & Srinivasan, P. (2017) · International Journal of Surgery · doi:10.1016/j.ijsu.2017.06.049 · Cited by 27
Jerusalem, G., Bachelot, T., Barrios, C., Neven, P., di Leo, A., Janni, W., & Boer, R. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.011 · Cited by 22
“Recently updated recommendations from the American Society of Clinical Oncology Clinical Practice Guidelines and the European School of Oncology-European Society for Medical Oncology (ESO-ESMO) 2nd International Consensus Guidelines for Advanced Breast Cancer recommend endocrine therapy as the preferred first-line tre…”
BackgroundSelf-citationAdvanced breast cancer clinical nursing curriculum: review and recommendations
Vila, C., Reñones, C., Ferro, T., Peñuelas, M. Á., Jiménez, M., Rodríguez-Lescure, Á., Muñoz-Mateu, M., & Colomer, R. (2016) · Clinical & Translational Oncology · doi:10.1007/s12094-016-1530-0 · Cited by 29
Caldeira, R., & Scazafave, M. (2016) · Oncology and Therapy · doi:10.1007/s40487-016-0033-z · Cited by 24
“Clinical guidelines produced by the joint European School of Oncology/European Society of Medical Oncology task force and by the National Comprehensive Cancer Network recommend that patients with hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative advanced breast cancer should be tre…”
BackgroundKirchner, J., Martin, O., Umutlu, L., Herrmann, K., Bittner, A., Hoffmann, O., Mohrmann, S., Gauler, T. C., Theurer, S., Antke, C., et al. (2020) · European Journal of Radiology · doi:10.1016/j.ejrad.2020.108975 · Cited by 25
Wang, Y., Rui, M., Guan, X., Cao, Y., & Chen, P. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.658747 · Cited by 27
Aldawsari, H. M., Singh, S., Alhakamy, N. A., Bakhaidar, R. B., Halwani, A. A., & Badr-Eldin, S. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101554 · Cited by 24
“It has been recommended that endocrine therapy be used first in treating females with ER+ advanced-stage breast cancer rather than chemotherapy, except in the event of rapidly progressing illness [6,7].”
BackgroundRetractedda Silva, T. L. (2016) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2016.03.004 · Cited by 28
Niwińska, A. (2016) · Clinical & Experimental Metastasis · doi:10.1007/s10585-016-9802-1 · Cited by 24
“In the recent issues of the American Society of Clinical Oncology [12], European Society for Medical Oncology [15] and other publications [13, 16, 17], there is no clear position stated on systemic treatment in these subgroups of patients.”
BackgroundTherapeutic approaches for protecting bone health in patients with breast cancer
Lüftner, D., Niepel, D., & Steger, G. G. (2017) · The Breast · doi:10.1016/j.breast.2017.10.007 · Cited by 24
Genre, L., Roche, H. H., Cagetti, L. V., Kanoun, D., Ouali, M., Filleron, T., & Dalenc, F. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.019 · Cited by 25
Llombart‐Cussac, A., Pérez-García, J. M., Borrego, M. R., Tolosa, P., Blanch, S., Fernández-Ortega, A., Urruticoechea, A., Blancas, I., Saura, C., Rojas, B., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102520 · Cited by 30
“…histologically con fi rmed HR+/HER2 − ABC (ABC de fi ned as metastatic disease or loco-regionally recurrent disease not amenable to curative therapy) 24 ; with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; with up to two prior lines of ET and up to one prior…”
Oral chemotherapy in advanced breast cancer: expert perspectives on its role in clinical practice
Cardoso, F., Colleoni, M. A., Leo, A. D., Francia, G., Gennari, A., Gligorov, J., & Llombart‐Cussac, A. (2016) · Cancer Treatment Communications · doi:10.1016/s2213-0896(16)06001-1 · Cited by 25
“Multiple parameters influence treatment choices for patients with metastatic breast cancer (MBC), including tumor biology, extent of disease, previous therapies, age, performance status, comorbidities, patient preference, and drug availability [1,2].”
BackgroundInfluentialSelf-citationGuidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)
Xu, B., & Ma, F. (2023) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2023.12.001 · Cited by 30
“13 , 25–28 The choice of endocrine therapy should be determined based on patients’ sensitivity to previous endocrine treatment, classified as: (1) endocrine treatment-naïve patients: unknown sensitivity and resistance to endocrine treatment; (2) primary resistance to endocrine treatment: recurrence…”
MethodSelf-citationFreedman, R. A., & Tolaney, S. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4560-6 · Cited by 28
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón, J. I., de la Cruz‐Merino, L., Gregori, J. G., de Dueñas, E. M., Oliveira, M., Seguí, M. Á., Álvarez, I., Antolín, S., Bellet, M., & López‐Tarruella, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02010-w · Cited by 31
Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Almstedt, K., & Schmidt, M. (2015) · Breast Care · doi:10.1159/000405017 · Cited by 22
P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice
Vieira, A. F., Dionísio, M. R., Gomes, M., Cameselle‐Teijeiro, J., Lacerda, M., Amendoeira, I., Schmitt, F. C., & Paredes, J. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.232 · Cited by 23
Prognostic role of Gli1 expression in breast cancer: a meta-analysis
Wang, B., Yu, T., Hu, Y., Xiang, M., Peng, H., Lin, Y., Han, L., & Zhang, L. (2017) · Oncotarget · doi:10.18632/oncotarget.19080 · Cited by 26
Cazzaniga, M. E., Airoldi, M., Arcangeli, V., Artale, S. A., Atzori, F., Ballerio, A., Bianchi, G., Blasi, L., Campidoglio, S., Ciccarese, M., et al. (2017) · The Breast · doi:10.1016/j.breast.2017.06.043 · Cited by 22
Experimental Therapy of Advanced Breast Cancer: Targeting NFAT1–MDM2–p53 Pathway
Qin, J., Wang, W., & Zhang, R. (2017) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2017.07.005 · Cited by 23
Li, H., Shao, B., Yan, Y., Song, G., Liu, X., Wang, J., & Xu, L. (2016) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2016.03.07 · Cited by 23
“The chemotherapy regimen was administered according to normal clinical practice and advanced breast cancer guidelines (11,12), and trastuzumab was continued after first-line trastuzumab progression unless the patients refuse treatment for cost, side effects or other factors, in which case chemotherapy agents were chan…”
MethodInari, H., Suganuma, N., Kawachi, K., Yoshida, T., Yamanaka, T., Nakamura, Y., Yoshihara, M., Nakayama, H., Yamanaka, A., Masudo, K., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3154-3 · Cited by 21
Brufsky, A., Mitra, D., Davis, K. L., Nagar, S. P., McRoy, L., Cotter, M. J., & Stearns, V. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.04.005 · Cited by 21
Association of Supporting Trial Evidence and Reimbursement for Off-Label Use of Cancer Drugs
Herbrand, A. K., Schmitt, A. M., Briel, M., Ewald, H., Goldkuhle, M., Diem, S., Hoogkamer, A., Joerger, M., Moffa, G., Novak, U., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.0380 · Cited by 20
“Melanoma, adjuvant, single agent First Nivolumab 16 16 (100) 0 Prostate cancer, advanced, drug combination First Abiraterone 14 11 (79) 1 (7) Glioblastoma, advanced, single agent Second, third, or beyond Lomustin 13 9 (69) 3 (23) Follicular lymphoma, induction, single agent First Rituximab 11 11 (100) 0 Multiple myelo…”
BackgroundThe Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters
Varzaru, V. B., Eftenoiu, A.-E., Vlad, D. C., Vlad, C. S., Moatar, A. E., Popescu, R., & Cobec, I. M. (2024) · Life · doi:10.3390/life14040458 · Cited by 33
“It is important to note that treatment decisions should not be based exclusively on a change in tumor markers [14,15].”
BackgroundSystemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines
Joy, A. A., Ghosh, M., Fernandes, R., & Clemons, M. J. (2015) · Current Oncology · doi:10.3747/co.22.2360 · Cited by 20
Zhang, F., & Cui, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10405 · Cited by 21
“Therefore, 11 patients with BRCA possessing a DFS ≤30 months were regarded as exhibiting ET resistance, while 21 patients exhibiting a DFS >100 months were regarded as sensitive to ET (57,58).”
BackgroundSteger, G. G., Egle, D., Bartsch, R., Pfeiler, G., Petru, E., Greil, R., Helfgott, R., Marth, C., Öhler, L., Hubalek, M., et al. (2020) · The Breast · doi:10.1016/j.breast.2020.01.035 · Cited by 22
“Endocrine therapy remains the mainstay for the treatment of advanced HRþ, HER2e breast cancer [4,5].”
BackgroundBayala, B., Zouré, A. A., Baron, S., de Joussineau, C., Simporè, J., & Lobaccaro, J. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103690 · Cited by 21
“crisis or another life-threatening situation requires chemotherapy [25].”
BackgroundUse of maintenance endocrine therapy after chemotherapy in metastatic breast cancer
Sutherland, S., Miles, D., & Makris, A. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.09.019 · Cited by 20
Koleva‐Kolarova, R., Greuter, M. J. W., van Kruchten, M., Vermeulen, K. M., Feenstra, T., Buskens, E., Glaudemans, A. W. J. M., de Vries, E. F. J., de Vries, E. F. J., Hospers, G. A. P., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.138 · Cited by 19
“…or in locally advanced inoperable breast cancer, positron emission tomography (PET) and CT (PET/CT) with 2-[18F]fluoro-2deoxy-D-glucose (FDG) is an acceptable option to further evaluate suspected MBC (Grassetto et al, 2011; Cardoso et al, 2012; NCCN Guidelines Version 3, 2014; Cardoso et al, 2014).”
BackgroundMatikas, A., Foukakis, T., & Bergh, J. C. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.04.002 · Cited by 19
Self-citationAsgari-Karchekani, S., Aryannejad, A., Mousavi, S. A., Shahsavarhaghighi, S., & Tavangar, S. M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01817-6 · Cited by 24
Xie, Y., Lv, X., Luo, C., Hu, K., Gou, Q., Xie, K., & Zheng, H. Y. (2017) · Medicine · doi:10.1097/md.0000000000007048 · Cited by 19
“The ABC guidelines also reported available data regarding the value of removal of the primary tumor in patients with stage IV.([7,21,37]) Our findings are in accordance with these reports analyzing the impact of surgery on survival.”
BackgroundMethodResultInfluentialChemotherapy Options beyond the First Line in HER-Negative Metastatic Breast Cancer
Lorusso, V., Latorre, A., & Giotta, F. (2020) · Journal of Oncology · doi:10.1155/2020/9645294 · Cited by 22
Forrai, G., Kovács, E. M., Ambrózay, É., Barta, M., Borbély, K., Lengyel, Z., Ormándi, K., Péntek, Z., Tasnádi, T., & Sebő, É. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610382 · Cited by 25
“The choice of imaging method is a joint decision of the attending physician and the radiologist, taking into account the possibility of visualization, availability, and reimbursement (9, 126, 127).”
MethodCurrent State of Cell Therapies for Breast Cancer
Gautam, N., Elleson, K. M., Ramamoorthi, G., & Czerniecki, B. J. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000607 · Cited by 21
Yang, X., Zhang, K., Zhang, C., Peng, R., & Sun, C. (2019) · BMC Cancer · doi:10.1186/s12885-019-5698-x · Cited by 19
“All the other studies with patients classified into MBC or ABC were grouped into the ABC subgroup.”
MethodClinical Review on the Management of Breast Cancer Visceral Crisis
Benvenuti, C., Gaudio, M., Jacobs, F., Saltalamacchia, G., Sanctis, R. D., Torrisi, R., Santoro, A., & Zambelli, A. (2023) · Biomedicines · doi:10.3390/biomedicines11041083 · Cited by 19
“The term “visceral crisis” was first adopted in the second ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 2) to indicate a condition of severe organ dysfunction that does not mean “the mere presence of visceral metastases, but implies important visceral compromise leading to a clinical ind…”
BackgroundLi, Z., Guo, S., Xue, H., Li, L., Guo, Y., Duan, S., & Zhu, H. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1183514 · Cited by 21
Metastatic breast cancer: The Odyssey of personalization
Sonnenblick, A., Ponde, N. F., & Piccart, M. J. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.002 · Cited by 20
“It is now agreed, based on expert opinion consensus, that patients progressing during the first two years of adjuvant hormonal therapy or during the first three months of hormonal therapy in the metastatic setting, should be classified as “primary endocrine resistant” (Cardoso et al., 2014).”
BackgroundSelf-citationTsuji, W., & Plock, J. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804003-4.00002-5 · Cited by 21
The role of abemaciclib in treatment of advanced breast cancer
McCartney, A., Moretti, E., Sanna, G., Pestrin, M., Risi, E., Malorni, L., Biganzoli, L., & Leo, A. D. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918776925 · Cited by 22
Self-citationWeekly paclitaxel—still preferred first-line taxane for mBC
Gligorov, J., & Richard, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.137 · Cited by 18
Self-citationBiopsy of breast cancer metastases: patient characteristics and survival
Shachar, S. S., Mashiach, T., Fried, G., Drumea, K. C., Shafran, N., Muss, H. B., & Bar‐Sela, G. (2017) · BMC Cancer · doi:10.1186/s12885-016-3014-6 · Cited by 18
“In addition, other factors are routinely used for therapy decisions, such as disease-free interval, site(s) of relapse, and number of metastases [2, 3].”
BackgroundOmori, Y., Enatsu, S., Cai, Z., & Ishiguro, H. (2019) · Breast Cancer · doi:10.1007/s12282-019-00965-4 · Cited by 17
Masiero, M. A., Spada, G. E., Sanchini, V., Munzone, E., Pietrobon, R. S., Teixeira, L., Valencia, M., Machiavelli, A., Fragale, E., Pezzolato, M., et al. (2023) · JMIR Research Protocols · doi:10.2196/48852 · Cited by 18
Yttrium-90 Radioembolization for Breast Cancer Liver Metastases
Gordon, A. C., Salem, R., & Lewandowski, R. J. (2016) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2016.06.016 · Cited by 17
Kawaguchi, H., Masuda, N., Nakayama, T., Aogi, K., Anan, K., Ito, Y., Ohtani, S., Sato, N., Saji, S., Tokunaga, E., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4212-x · Cited by 16
“This result supports the ESO– ESMO guidelines’ statement of intrinsic or primary endocrine resistance for early breast cancer, if defined as recurrence within the first 2 years of adjuvant endocrine therapy [14].”
ResultWu, F., Shi, C., Wu, R., Huang, Z., & Chen, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.17696 · Cited by 18
“The primary end-points were disease-free survival (DFS) and overall survival (OS) [17, 18].”
BackgroundBan, M., Miše, B. P., Majić, A., Dražić, I., & Vrdoljak, E. (2017) · Future Oncology · doi:10.2217/fon-2017-0491 · Cited by 17
Ortega, V., Antón, A., Garau, I., Afonso, N., Calvo, L., Fernández, Y., Martinez‐García, M., Blanco, E., Zamora, P. M., García, M., et al. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.12.012 · Cited by 17
Inari, H., Suganuma, N., Kawachi, K., Yoshida, T., Yamanaka, T., Nakamura, Y., Yoshihara, M., Nakayama, H., Masudo, K., Oshima, T., et al. (2017) · Breast Cancer · doi:10.1007/s12282-017-0774-z · Cited by 20
Kalaiarasi, C., Saravanan, M., & Kumaradhas, P. (2019) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2019.1574605 · Cited by 17
Zhang, D., Lü, W., Zhuo, Z., Wang, Y., Zhang, W., & Zhang, M. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01511-0 · Cited by 18
“The definition of intrinsic/acquired ET resistance was first clarified at the European society for medical oncology (ESMO) in 2014 [34].”
BackgroundLee, E. Y., Lee, D., Lee, K.-H., & Im, S. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.846 · Cited by 19
“…based on primary or secondary endocrine therapy resistance as defined by the European School of Oncology (ESO)/ European Society of Medical Oncology (ESMO) guidelines [36], the specific PFS and OS values for patients who progressed on endocrine therapy for advanced breast cancer are unknown.”
Boér, K. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s77033 · Cited by 19
“Until recently, the only hormonal strategies in clinical use were tamoxifen, aromatase inhibitors, and fulvestrant used alone.(3,4) Even though endocrine therapy is the most effective treatment for ER+ve/HER2-ve tumors, up to a quarter may show de novo resistance to hormone therapies or acquired resistance during the…”
MethodBøttcher, T. M., Cold, S., & Jensen, A. B. (2018) · Acta Oncologica · doi:10.1080/0284186x.2018.1532603 · Cited by 17
“The treatment of MBC is not curative but palliative, focusing on optimizing survival time and quality of life and limiting adverse events [2].”
BackgroundBeyond Chemotherapies: Recent Strategies in Breast Cancer Treatment
Foulon, A., Theret, P., Rodat‐Despoix, L., & Kischel, P. (2020) · Cancers · doi:10.3390/cancers12092634 · Cited by 18
“Endocrine therapy is also the reference for non-symptomatic metastatic situation [76].”
BackgroundLiu, Z., Mi, M., Zheng, X., Zhang, C., Zhu, F., Liu, T., Wu, G., & Zhang, L. (2021) · Journal of Cancer · doi:10.7150/jca.57752 · Cited by 18
“Although advances in systemic and comprehensive therapy, especially molecular targeted therapy, have significantly improved the survival of breast cancer patients, the median survival time of patients with metastatic breast cancer is still only 2-3 years [2].”
BackgroundYin, W., Pei, G., Liu, G., Huang, L., Gao, S., & Feng, X. (2015) · Oncotarget · doi:10.18632/oncotarget.5460 · Cited by 16
Zhang, J., Huang, Y., Wang, C., He, Y., Zheng, S., & Wu, K. (2017) · Medicine · doi:10.1097/md.0000000000007846 · Cited by 20
“ABC comprises both inoperable locally ABC (LABC) and metastatic breast cancer (MBC) or stage IV.”
MethodWigginton, B., Thomson, Z. O., Sandler, C. X., & Reeves, M. M. (2019) · Qualitative Health Research · doi:10.1177/1049732319884901 · Cited by 16
“Therefore, optimizing both length and quality of survival are primary goals of care (Cardoso et al., 2014).”
BackgroundGoyal, R., Carter, G. C., Nagar, S. P., Smyth, E. N., Price, G. L., Parikh, R. C., Huang, Y., Li, L., Davis, K. L., & Kaye, J. A. (2020) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2020.1804871 · Cited by 17
“with the national guidelines and other recommendations that patients with visceral disease should be considered for initial treatment with chemotherapy [6,7].”
BackgroundTargets for Neoadjuvant Therapy – The Preferences of Patients with Early Breast Cancer
Thill, M., Pisa, G., & Isbary, G. (2016) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0042-101025 · Cited by 17
“Basically NACT can be carried out when the indication for chemotherapy exists even before an operation [1,2,7].”
Shi, J., Du, S., Wang, R., Gao, H., Luo, Q., Hou, G., Zhou, Y., Zhu, Z., & Wang, F. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-022-03865-y · Cited by 17
“The European guidelines have already recommended the biopsy of metastases to reassess the HER2 status [44], but in clinical practice, this is not easy, and it is impossible when multiple metastases exist.”
BackgroundThe emerging role of advanced neuroimaging techniques for brain metastases.
Nowosielski, M., & Radbruch, A. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.05.04 · Cited by 17
“Brain imaging should not be carried out routinely in metastatic breast cancer patients, if the patient is asymptomatic (28) and also for melanoma patients there is currently no consensus on the frequency of follow-up (29).”
BackgroundFarhat, F., Kattan, J. G., & Ghosn, M. G. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3027-5 · Cited by 15
“According to the latest versions of international guidelines [9, 10], preferred first-line combinations in MBC include the combination of vinorelbine [3] and trastuzumab [7].”
MethodLobbezoo, D. J. A., Truin, W., Voogd, A. C., Roumen, R. M. H., Vreugdenhil, G., Dercksen, M. W., van den Berkmortel, F. W. P. J., Smilde, T. J., van de Wouw, A. J., van Kampen, R. J. W., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8838 · Cited by 15
Ampullary Metastasis From Breast Cancer: A Rare Cause of Obstructive Jaundice
Giestas, S., Lopes, S., Souto, P., Agostinho, C., Camacho, E., Cipriano, M. A., & Sofia, C. (2016) · GE Portuguese Journal of Gastroenterology · doi:10.1016/j.jpge.2016.03.001 · Cited by 15
Pritchard, K. I., Chia, S., Simmons, C. E., McLeod, D., Paterson, A. H. G., Provencher, L., & Rayson, D. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0185 · Cited by 15
Koleva‐Kolarova, R., Greuter, M. J. W., Feenstra, T., Vermeulen, K. M., de Vries, E. F. J., Parkin, D. W., Buskens, E., & de Bock, G. H. (2018) · Oncotarget · doi:10.18632/oncotarget.24869 · Cited by 16
“Human epidermal growth factor receptor 2 (HER2-) and hormone receptor (HR–estrogen receptor (ER) and progesterone receptor (PR)) targeted and hormonal therapies are recommended for patients with tumors that express these receptors [1, 2].”
Wang, M., Zhang, Y., Xu, Z., Qian, P., Sun, W., Wang, X., Zhang, J., Xia, T., Xu, Y., & Tang, J. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00613-x · Cited by 18
Exploring the concepts and practices of advanced breast cancer treatment: a narrative review
Wang, X., Shao, X., Huang, J., Lei, L., Huang, Y., Zheng, Y., Cao, W., & Chen, Z. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1458 · Cited by 14
“The ABC2 guidelines (3) issued in 2014 were updated in various respects, and many new recommendations were provided for the treatment of patients with triple-negative breast cancer (TNBC), HER2-positive breast cancer, and hormone receptor (HR)-positive breast cancer.”
BackgroundTonissi, F., Lattanzio, L., Merlano, M. C., Infante, L., Nigro, C. L., & Garrone, O. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0249-z · Cited by 13
“Taxanes are among the most active drugs in the treatment of metastatic breast cancer (MBC) and are established as the standard of care either as monotherapy or in combination with other cytotoxic agents [1, 2].”
BackgroundKomatsu, H., Yagasaki, K., & Yamaguchi, T. (2016) · BMC Nursing · doi:10.1186/s12912-016-0130-1 · Cited by 15
“The systematic treatment options for MBC are endocrine therapy, chemotherapy, and biological (targeted) therapy [3].”
BackgroundGong, C., Zhao, Y.-N., Wang, B.-Y., Hu, X.-C., Wang, Z.-H., Zhang, J., & Zhang, S. (2017) · OncoTarget · doi:10.18632/oncotarget.16336 · Cited by 12
“Primary endocrine resistance was defined as: a relapse during the first 2 years of adjuvant ET, or progress within first 6 months of first-line ET for MBC. Secondary endocrine resistance was defined as: a relapse during adjuvant ET but after the first 2 years, or a relapse within 12 months of completing adjuvant ET, o…”
BackgroundInfluentialTumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
Miragaya, J. G., & González‐Suárez, E. (2017) · Molecular & Cellular Oncology · doi:10.1080/23723556.2017.1338208 · Cited by 15
“Mainstay treatment is chemotherapy, mostly anthracyclines and taxanes.(1,2) The major cause of death is not the primary tumor but the metastases, which normally display resistance to treatment.”
BackgroundRecent advances in the medical treatment of breast cancer
Vorobiof, D. (2016) · F1000Research · doi:10.12688/f1000research.9619.1 · Cited by 13
Self-citationU.S. Prevalence of Endocrine Therapy–Naïve Locally Advanced or Metastatic Breast Cancer
Nunes, A. P., Liang, C., Gradishar, W. J., Dalvi, T. B., Lewis, J., Jones, N., Green, E., Doherty, M., & Seeger, J. D. (2019) · Current Oncology · doi:10.3747/co.26.4163 · Cited by 14
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care
Schneider, D. J., Bianchini, G., Horgan, D., Michiels, S., Witjes, W. P. J., Hills, R. K., Plun-Favreau, J., Brand, A. M., & Lawler, M. (2015) · Public Health Genomics · doi:10.1159/000441556 · Cited by 14
Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
Ro, J., Cheng, F. T.-F., Sriuranpong, V., Villalon, A. H., Smruti, B. K., Tsang, J. W. H., & Yap, Y. S. (2016) · Journal of Breast Cancer · doi:10.4048/jbc.2016.19.1.8 · Cited by 13
Schmidt, M. (2015) · Breast Care · doi:10.1159/000442726 · Cited by 13
Niraula, S., & Ocaña, A. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.09.011 · Cited by 13
“This finding contradicts the usual consensus where single agent sequential treatment is favored in women with limited disease, particularly in those with asymptomatic or minimally symptomatic boneonly metastases [17].”
ResultSabale, U., Ekman, M., Thunström, D., Telford, C., & Livings, C. (2017) · PharmacoEconomics - Open · doi:10.1007/s41669-017-0031-6 · Cited by 14
“treatment guidelines among the recommended ETs in metastatic BC as a second- and later-line treatment [6, 7, 39, 40].”
BackgroundChalasani, P. (2017) · Oncology · doi:10.1159/000477404 · Cited by 13
Readdressing the Role of Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer
Khan, S. A., & DesJardin, E. S. M. (2018) · Cancer treatment and research · doi:10.1007/978-3-319-70197-4_6 · Cited by 12
Marschner, N. W., Salat, C., Söling, U., Hansen, R., Grebhardt, S., Harde, J., Nusch, A., & Potthoff, K. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.010 · Cited by 13
Shi, W., Wang, X., Bi, X., Xia, W., Huang, J., Su, Y., Huang, Z., & Yuan, Z. (2019) · Journal of Cancer Therapy · doi:10.4236/jct.2019.102011 · Cited by 13
“Except for cases with visceral metastasis, larger tumor burden and rapid growing tumors, guidelines recommend endocrine therapy as the preferred treatment option for hormone receptor (HR)-positive advanced breast cancer (ABC) [4] [5].”
BackgroundWang, Y., Lu, J. M., Li, Y., Sun, T., Wan, D., Sheng, L., Li, W., & Zhu, H. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s91166 · Cited by 13
“51 However, the impact of receptor conversion on clinical outcome remains unclear; in a pooled analysis, only a minority of patients (14”
Marchetti, P., Maass, N., Gligorov, J., Berger, K., MacDougall, F., Montonen, J., & Lewis, J. (2016) · The Breast · doi:10.1016/j.breast.2016.12.002 · Cited by 14
“ESO-ESMO clinical guidelines [4] suggest that endocrine therapy should be used preferentially in patients with HR-positive, HER2negative MBC, and chemotherapy should be reserved for patients with rapidly progressing disease or for those likely to be resistant to endocrine therapy.”
BackgroundMethodSelf-citationXu, B., Zhang, Q., Luo, Y., Tong, Z., Sun, T., Shan, C., Liu, X., Yao, Y., Zhao, B., Wang, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56096-2 · Cited by 20
“These fi ndings support the application of lerociclib plus fulvestrant as a treatment option for patients with HR +/HER2 − ABC whose disease had progressed on prior ET.”
InfluentialSelf-citationA phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
Sakiyama, T., Tsurutani, J., Iwasa, T., Kawakami, H., Nonagase, Y., Yoshida, T., Tanaka, K., Fujisaka, Y., Kurata, T., Komoike, Y., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.10 · Cited by 12
“Indeed, MBC treatment guidelines recommend combination chemotherapy in these cases (Cardoso et al, 2014; Partridge et al, 2014).”
BackgroundWander, S. A., Mayer, E. L., & Burstein, H. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.9482 · Cited by 13
Liedtke, C., Thill, M., Hanf, V., & Schütz, F. (2015) · Breast Care · doi:10.1159/000431248 · Cited by 12
Chocteau-Bouju, D., Chakiba, C., Mignot, L., Madranges, N., Pierga, J., Beuzeboc, P., Quénel-Tueux, N., Dieras, V. C., Bonnefoi, H. R., Debled, M., et al. (2015) · The Breast · doi:10.1016/j.breast.2015.09.002 · Cited by 14
Reinvention of chemotherapy: drug conjugates and nanoparticles
Nguyen‐Ngoc, T., & Raymond, É. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000183 · Cited by 12
Metadata
- Authors
- Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., Cardoso, M. J., Cufer, T., El Saghir, N., Fallowfield, L., Fenech, D., Francis, P., Gelmon, K., Giordano, S. H., Gligorov, J., Goldhirsch, A., Harbeck, N., Houssami, N., Hudis, C., Kaufman, B., Krop, I., Kyriakides, S., Lin, U. N., Mayer, M., Merjaver, S. D., Nordström, E. B., Pagani, O., Partridge, A., Penault-Llorca, F., Piccart, M. J., Rugo, H., Sledge, G., Thomssen, C., van't Veer, L., Vorobiof, D., Vrieling, C., West, N., Xu, B., & Winer, E.
- Affiliations
- Centro Champalimaud (PT)
- European School of Oncology (CH)
- Memorial Sloan Kettering Cancer Center (US)
- Gdańsk Medical University (PL)
- Clinique de Genolier (CH)
- Institut Gustave Roussy (FR)
- Pontifícia Universidade Católica do Rio Grande do Sul (BR)
- Karolinska University Hospital (SE)
- Fondazione Sandro Pitigliani (IT)
- Duke University (US)
- Champalimaud Foundation (PT)
- Brighton and Sussex Medical School (GB)
- Europa Donna (IT)
- Peter MacCallum Cancer Centre (AU)
- BC Cancer Agency (CA)
- The University of Texas MD Anderson Cancer Center (US)
- Université Pierre-et-Marie-Curie (FR)
- European Institute of Oncology (IT)
- Ludwig-Maximilians-Universität München (DE)
- The University of Sydney (AU)
- Sheba Medical Center (IL)
- Dana-Farber Cancer Institute (US)
- University of Michigan (US)
- Europa Donna (GE)
- Istituto Oncologico della Svizzera Italiana (CH)
- Centre Jean Perrin (FR)
- Institut Jules Bordet (BE)
- University of California, San Francisco (US)
- Indiana University (US)
- Martin Luther University Halle-Wittenberg (DE)
- Cardiff and Vale University Health Board (GB)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Corresponding author
- Cardoso, F.
- ORCID
- Cardoso, F.
- Costa, A.
- Norton, L.
- Senkus, E.
- Aapro, M.
- André, F.
- Barrios, C.H.
- Bergh, J.
- Biganzoli, L.
- Cardoso, M.J.
- Fallowfield, L.
- Francis, P.
- Gelmon, K.
- Giordano, S.H.
- Gligorov, J.
- Harbeck, N.
- Houssami, N.
- Hudis, C.
- Kaufman, B.
- Krop, I.
- Pagani, O.
- Partridge, A.
- Penault-Llorca, F.
- Piccart, M.J.
- Rugo, H.
- Sledge, G.
- Thomssen, C.
- Vorobiof, D.
- Vrieling, C.
- Xu, B.
- Winer, E.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 25
- Issue
- 10
- Pages
- 1871-1888
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC4176456
- OpenAlex
- W2127287298
- Cited by
- 540
- References
- 143
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 15 · 2023: 23 · 2022: 20 · 2021: 24 · 2020: 38 · 2019: 37 · 2018: 57 · 2017: 107 · 2016: 124 · 2015: 84 · 2014: 2
- FWCI
- 33.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1878 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Sussex Research Online (University of Sussex) (submittedVersion, cc-by-nc-nd)
- OAR@UM (University of Malta) (submittedVersion, other-oa)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion, other-oa)
- Figshare (submittedVersion, cc-by-nc-nd)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- advanced breast cancer, metastatic breast cancer, treatment guidelines, HER2-positive breast cancer, luminal breast cancer, overall survival, quality of life, standard of care, unmet medical needs, research priorities
- MeSH terms
- Breast Neoplasms, Female, Humans, Treatment Outcome, Guidelines as Topic, Neoplasm Grading
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.